⚠ Evidence warning: Clinical trials or other evidence do not support the claims that the European and American Thyroid Associations recommend selenium for mild active Graves' orbitopathy and that this is one of the strongest guideline endorsements of selenium for any thyroid condition. This page keeps it as a report of what people, websites or other media say.

Selenium for Thyroid Function

Selenium and Thyroid Function — scientific infographic poster

The thyroid gland contains more selenium per gram of tissue than any other organ in the human body. This remarkable concentration reflects the thyroid's profound dependence on selenoproteins for both hormone synthesis and self-protection. At least eleven selenoproteins are expressed in thyroid tissue, including the three iodothyronine deiodinases that control thyroid hormone activation and inactivation, the glutathione peroxidases that protect thyrocytes from oxidative damage, and the thioredoxin reductases that maintain cellular redox balance. Selenium deficiency impairs thyroid function at multiple levels, and the interplay between selenium and iodine status has significant clinical implications for thyroid health worldwide.

Table of Contents

  1. Key Benefits at a Glance
  2. Deiodinase Enzymes
  3. Type 1 Deiodinase (DIO1)
  4. Type 2 Deiodinase (DIO2)
  5. Type 3 Deiodinase (DIO3)
  6. Thyroid Peroxidase Protection
  7. Autoimmune Thyroid Disease
  8. Hashimoto’s Thyroiditis
  9. Graves’ Disease and Orbitopathy
  10. Selenium Deficiency and Thyroid Dysfunction
  11. Combined Selenium and Iodine Deficiency
  12. Clinical Evidence for Supplementation
  13. Dosing and Forms
  14. Safety and Considerations
  15. Key Research Papers
  16. Connections
  17. Featured Videos

Key Benefits at a Glance

Back to Table of Contents

Deiodinase Enzymes: Regulators of Thyroid Hormone Activation

The thyroid gland primarily secretes thyroxine (T4), a prohormone with relatively low biological activity. Conversion of T4 to the metabolically active triiodothyronine (T3) depends on selenium-containing deiodinase enzymes. These selenoenzymes catalyze the removal of specific iodine atoms from the thyronine ring structure, thereby activating or inactivating thyroid hormones in a tissue-specific manner.

Type 1 Deiodinase (DIO1)

DIO1 is a plasma membrane-associated selenoenzyme expressed predominantly in the liver, kidneys, and thyroid gland. It catalyzes both outer ring deiodination (converting T4 to T3) and inner ring deiodination (converting T4 to reverse T3, or rT3). DIO1 contributes to the T3 circulating in the blood, but a 2005 study estimated that in people with normal thyroid function DIO2 makes more of the T3 produced outside the thyroid (about 29 nmol a day, against about 15 nmol from DIO1); DIO1 supplies most of it (about 67%) only in people with an overactive thyroid (Maia 2005). In the thyroid gland itself, DIO1 participates in local T3 generation and iodine salvage by deiodinating iodothyronine metabolites, allowing the released iodide to be recycled for new hormone synthesis.

DIO1 expression is positively regulated by T3 itself, creating a feedforward mechanism that increases T4-to-T3 conversion when thyroid hormone levels are adequate. In selenium deficiency, reduced DIO1 activity leads to elevated serum T4 and decreased T3, with a corresponding increase in rT3 levels, a pattern that can mimic nonthyroidal illness syndrome.

Type 2 Deiodinase (DIO2)

DIO2 is an endoplasmic reticulum-resident selenoenzyme responsible for local T3 production in tissues that are highly sensitive to thyroid hormone levels. It is expressed in the brain, anterior pituitary, thyroid, brown adipose tissue, skeletal muscle, and placenta. DIO2 exclusively catalyzes outer ring deiodination, converting T4 to T3 with high efficiency even when T4 levels are low (a low Km, meaning a high affinity for its substrate). In people with normal thyroid function it is estimated to be the major source of the T3 in the blood (Maia 2005).

In the brain, DIO2 activity in astrocytes and tanycytes generates the T3 that is critical for neuronal function, myelination, and neurotransmitter metabolism. In the anterior pituitary, DIO2-generated T3 mediates the negative feedback regulation of thyroid-stimulating hormone (TSH) secretion. A critical feature of DIO2 regulation is its rapid proteasomal degradation in response to its substrate T4, providing a homeostatic mechanism that adjusts local T3 production inversely to circulating T4 levels. Polymorphisms in the DIO2 gene (Thr92Ala) have been associated with altered thyroid hormone metabolism and clinical outcomes in hypothyroid patients on levothyroxine therapy.

Type 3 Deiodinase (DIO3)

DIO3 is the primary thyroid hormone-inactivating deiodinase. It catalyzes inner ring deiodination, converting T4 to rT3 and T3 to 3,3'-diiodothyronine (T2), both of which have minimal biological activity at thyroid hormone receptors. DIO3 is the most abundant deiodinase during fetal development, where it protects developing tissues from premature and excessive exposure to thyroid hormones. In the adult, DIO3 is expressed in the brain, skin, and placenta, and its expression can be markedly upregulated during critical illness, contributing to the low T3 state observed in nonthyroidal illness syndrome.

Coordinated Deiodinase Function

The three deiodinases work in concert to maintain precise thyroid hormone homeostasis at both the systemic and local tissue levels. In selenium deficiency, the hierarchy of selenoprotein expression ensures that DIO2 and DIO3 in the brain are relatively preserved at the expense of DIO1 in peripheral tissues. This prioritization reflects the critical importance of maintaining thyroid hormone homeostasis in the central nervous system. Nonetheless, prolonged or severe selenium deficiency can compromise all deiodinase activities, leading to widespread thyroid hormone dysregulation.

Back to Table of Contents

Thyroid Peroxidase Protection

Thyroid hormone synthesis is an oxidative process that generates substantial amounts of hydrogen peroxide (H2O2). The enzyme thyroid peroxidase (TPO) uses H2O2 as a co-substrate to oxidize iodide for incorporation into thyroglobulin (iodination) and to couple iodotyrosine residues to form T4 and T3 (coupling reaction). The dual oxidase enzymes DUOX1 and DUOX2 at the apical membrane of thyrocytes generate the H2O2 required for these reactions.

While H2O2 is essential for hormone synthesis, its excess poses a severe oxidative threat to thyrocytes. Uncontrolled H2O2 accumulation can damage cellular lipids, proteins, and DNA, leading to thyrocyte injury, apoptosis, and ultimately fibrosis. The thyroid gland relies heavily on selenoproteins to manage this oxidative burden.

When selenium is deficient, the capacity to neutralize H2O2 is diminished. The resulting oxidative stress causes thyrocyte damage, promotes inflammatory infiltration, and may trigger autoimmune responses against damaged thyroid antigens. This mechanism is believed to contribute to the pathogenesis of autoimmune thyroid diseases, particularly in populations with combined selenium and iodine deficiency.

Back to Table of Contents

Autoimmune Thyroid Disease

Autoimmune thyroid diseases, including Hashimoto's thyroiditis and Graves' disease, are the most common organ-specific autoimmune disorders worldwide. A growing body of evidence implicates selenium deficiency as a contributing factor in their development and progression.

Hashimoto's Thyroiditis

Hashimoto's thyroiditis (chronic lymphocytic thyroiditis) is characterized by progressive autoimmune destruction of the thyroid gland, leading to hypothyroidism. The disease involves infiltration of the thyroid by autoreactive lymphocytes and the production of antibodies against thyroid peroxidase (anti-TPO antibodies) and thyroglobulin (anti-Tg antibodies).

Selenium deficiency may promote Hashimoto's thyroiditis through several mechanisms:

Multiple clinical trials have investigated selenium supplementation in Hashimoto's thyroiditis. Several randomized controlled trials have demonstrated that supplementation with 200 micrograms of sodium selenite or selenomethionine daily for 3 to 12 months can significantly reduce anti-TPO antibody titers in patients with Hashimoto's thyroiditis, compared to placebo. Some trials have also reported improvements in thyroid ultrasound appearance (reduced echogenicity, indicating decreased inflammation) and improved quality of life measures. However, results have been heterogeneous across studies, and the degree of benefit may depend on baseline selenium status, with the greatest improvements observed in populations with lower initial selenium levels.

Graves' Disease

Graves' disease is caused by stimulating autoantibodies directed against the thyroid-stimulating hormone receptor (thyrotropin receptor antibodies, TRAb), leading to hyperthyroidism, diffuse goiter, and in some cases, orbitopathy (Graves' ophthalmopathy). The role of selenium in Graves' disease is particularly notable in the context of Graves' orbitopathy.

Back to Table of Contents

Selenium Deficiency and Thyroid Dysfunction

The consequences of selenium deficiency on thyroid function are determined by the severity and duration of deficiency, concurrent iodine status, and individual genetic factors.

Isolated Selenium Deficiency

In populations with adequate iodine intake, isolated selenium deficiency primarily affects peripheral thyroid hormone metabolism. Characteristic findings include:

Combined Selenium and Iodine Deficiency

The interaction between selenium and iodine deficiency is clinically significant and geographically relevant, as regions with selenium-poor soils often also have iodine-deficient populations. Combined deficiency produces more severe thyroid dysfunction than either deficiency alone.

Back to Table of Contents

Clinical Evidence for Selenium Supplementation

A substantial and growing body of clinical evidence supports the role of selenium supplementation in thyroid health, although important questions remain regarding optimal dose, form, duration, and patient selection.

Evidence in Autoimmune Thyroiditis

Evidence in Graves' Orbitopathy

Evidence in Pregnancy

Considerations and Limitations

Back to Table of Contents

Dosing and Forms

Back to Table of Contents

Safety and Considerations

This content is provided for informational purposes only and does not constitute medical advice. The adult upper limit for selenium is 400 mcg a day from all sources combined, and chronic intake above it can cause selenosis (garlic breath, brittle nails, hair loss).

Back to Table of Contents

Key Research Papers

  1. Rayman MP. Selenium and human health. Lancet. 2012;379(9822):1256-1268. — doi:10.1016/S0140-6736(11)61452-9
  2. Köhrle J. Selenium and the thyroid. Curr Opin Endocrinol Diabetes Obes. 2015;22(5):392-401. — doi:10.1097/MED.0000000000000190
  3. Gärtner R, Gasnier BC, Dietrich JW, et al. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab. 2002;87(4):1687-1691. — doi:10.1210/jc.87.4.1687
  4. Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med. 2011;364(20):1920-1931. — doi:10.1056/NEJMoa1012985
  5. Negro R, Greco G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. J Clin Endocrinol Metab. 2007;92(4):1263-1268. — doi:10.1210/jc.2006-1821
  6. van Zuuren EJ, Albusta AY, Fedorowicz Z, Carter B, Pijl H. Selenium supplementation for Hashimoto’s thyroiditis. Cochrane Database Syst Rev. 2013;(6):CD010223. — doi:10.1002/14651858.CD010223.pub2
  7. Wichman J, Winther KH, Bonnema SJ, Hegedus L. Selenium supplementation significantly reduces thyroid autoantibody levels in patients with chronic autoimmune thyroiditis: a systematic review and meta-analysis. Thyroid. 2016;26(12):1681-1692. — doi:10.1089/thy.2016.0256
  8. Duntas LH, Benvenga S. Selenium: an element for life. Endocrine. 2015;48(3):756-775. — doi:10.1007/s12020-014-0477-6
  9. Schomburg L. Dietary selenium and human health. Nutrients. 2017;9(1):22. — doi:10.3390/nu9010022
  10. Maia AL, Kim BW, Huang SA, Harney JW, Larsen PR. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest. 2005;115(9):2524-2533. — doi:10.1172/JCI25083
  11. Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185(4):G43-G67. — doi:10.1530/EJE-21-0479
  12. Huwiler VV, Maissen-Abgottspon S, Stanga Z, et al. Selenium supplementation in patients with Hashimoto thyroiditis: a systematic review and meta-analysis of randomized clinical trials. Thyroid. 2024;34(3):295-313. — doi:10.1089/thy.2023.0556
  13. PubMed — selenium + Hashimoto + randomized trials
  14. PubMed — selenium + Graves’ orbitopathy
  15. NIH Office of Dietary Supplements — Selenium Fact Sheet for Health Professionals
  16. Linus Pauling Institute — Selenium

Back to Table of Contents

Connections

Back to Table of Contents